CAR T-Cell Therapy Shows Durable One-Year Mobility Improvement in Stiff Person Syndrome Trial

Standard neurological consensus has long maintained that severe autoimmune mobility disorders like Stiff Person Syndrome (SPS) are relentlessly progressive conditions requiring lifelong, daily immunosuppression just to slow the decline. But one-year clinical trial data released Thursday directly challenges that ceiling on recovery. Results from Kyverna Therapeutics demonstrate that a single infusion of an engineered cellular therapy, miv-cel, produces durable, drug-free mobility improvements a full 12 months post-treatment.[1][2]

The new data marks a critical milestone in the application of chimeric antigen receptor (CAR) T-cell therapy outside of oncology. Originally developed to hunt blood cancers, the modified T-cells in miv-cel are instead programmed to seek out and deplete the autoreactive B cells responsible for attacking the nervous system in patients with SPS and generalized Myasthenia Gravis (gMG).[1][4]

At the one-year mark, patients who received the therapy maintained significant functional gains. For individuals with SPS—a condition characterized by debilitating muscle spasms and progressive rigidity that often confines patients to wheelchairs—the treatment restored walking ability and drastically reduced stiffness. Crucially, these improvements were sustained without the patients requiring their previous regimens of chronic immunosuppressive drugs.[2][4]

This sustained, drug-free response indicates that the therapy may effectively reset the immune system rather than merely suppressing it temporarily. By clearing out the specific B cells producing the autoantibodies, miv-cel allows the body to repopulate a healthy, non-reactive B cell compartment. The 12-month data confirms that this newly generated immune population has not reverted to attacking the patients' nervous systems.[1][5]

The durability of these mobility improvements arrives at a crucial moment for the broader autoimmune CAR-T landscape. While the field has generated immense excitement over the past two years, several peer therapies have recently encountered safety snags, prompting regulatory scrutiny over severe neurotoxicity and the theoretical risk of secondary malignancies.[3]

Against that backdrop, Kyverna reported a favorable safety profile for miv-cel at the 12-month checkpoint. The company noted that the therapy was well-tolerated, with no new safety signals or delayed adverse events emerging since the initial acute post-infusion period. The published trial updates did not include direct commentary or quotations from the principal investigators, but the safety data stands as a critical metric for moving the therapy toward eventual regulatory approval.[1][3]

For patients managing autoimmune-driven mobility loss, the results offer a tangible shift in long-term prognosis. While miv-cel remains in clinical trials and is not yet available for general prescription, the one-year durability data provides strong evidence that a single cellular intervention could eventually replace daily symptom management.[2][4]

Patients currently relying on chronic immunosuppression must continue their prescribed regimens, as the therapy is still navigating the clinical pipeline. However, the trial will continue to track participants to determine if the immune reset holds at the two- and three-year marks, while researchers expand the miv-cel program to evaluate its efficacy in other severe autoimmune conditions.[1][5]